Targeted Therapeutics that Address Unmet Medical Needs

Inflammatory Bowel Disease (IBD) is complex and heterogeneous. A ‘one-size-fits-all’ standardized treatment may not be effective for many patients. In fact, 75% of the 2 million patients in the US who have IBD are refractory to first line biologic therapy¹.

Prometheus Biosciences is pioneering a precision medicine approach for the treatment of IBD. We merge access to hundreds of thousands of patient samples with advances in machine learning and data mining tools to understand the link between patients’ symptoms and disease-driving biomarkers. We use these breakthroughs to identify novel therapeutic targets and diagnostic tests to address the unmet medical needs. 

Therapeutic Pipeline

Lead Optimization
Phase 1
Phase 2
Phase 3
PRA023 - Anti-TL1A mAb for UC and CD
PR600 - Anti-TNF Super Family Member mAb for IBD
Europe Partnered
PR300 - GPCR Modulator Small Molecule for IBD

Prometheus has an early-stage discovery collaboration with Takeda Pharmaceuticals.

PRA023 Phase 1
PR600 Lead Optimization
PR300 Lead Optimization